RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN

DRUG4 trials

Sponsors

St. Anna Childrens Cancer Research Institute GmbH, Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S, Ospedale San Raffaele S.r.l., Nefro Avillion Clinical Development LLC

Conditions

Acute Lymphoblastic LeukaemiaRelapsing Remitting Multiple SclerosisRenal Transplantationnew-onset autoimmune type 1 diabetes

Phase 2

ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia

RecruitingCTIS2024-512657-24-00

St. Anna Childrens Cancer Research Institute GmbHAcute Lymphoblastic Leukaemia

Start: 2014-03-27Target: 1108Updated: 2025-11-18

NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY

RecruitingCTIS2024-515470-26-00

Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et SRelapsing Remitting Multiple Sclerosis

Start: 2024-10-31Target: 90Updated: 2025-11-17

A phase 2b, single-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of oral Ladarixin in association with a single low dose of Antithymocyte Globulin in patients with new-onset autoimmune type 1 diabetes.

WithdrawnCTIS2025-524298-18-00

Ospedale San Raffaele S.r.l.new-onset autoimmune type 1 diabetes

Target: 46Updated: 2026-04-09

A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)

Not yet recruitingCTIS2026-525646-29-00

Nefro Avillion Clinical Development LLCRenal Transplantation

Target: 8Updated: 2026-08-26